GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherap
AstraZeneca’s efforts to combine two of its top cancer drugs – Imfinzi and Lynparza – has been rewarded with positive results in an endometrial cancer study that could lea
The NHS has agreed a pair of commercial deals with Merck & Co/MSD and Eisai that will allow hundreds of women with advanced endometrial cancer to get access to life-ex
GSK and Merck & Co have both reported new clinical data with the PD-1 checkpoint inhibitors, seeking an edge in the first-line treatment of advanced endometrial cancer
GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company